
Glauconix Biosciences, a NY-based software company, innovates in ophthalmic drug development.
Glauconix Biosciences, founded in Albany, New York, operates from the SUNY Polytechnic Institute campus. The company specializes in ophthalmic drug development, leveraging a proprietary platform technology to reduce costs and accelerate the process. Their core mission is to advance eye care by providing innovative solutions for drug testing and development. Glauconix offers various models, including glaucoma and retinal vascular dysfunction models, to support pharmaceutical research and development.
Notable figures associated with Glauconix include experts from the fields of ophthalmology and pharmaceutical sciences. The company has secured investments from prominent biotech investors and has received recognition for its contributions to reducing the time and cost of drug development. Glauconix's impact is significant in the pharmaceutical industry, providing advanced tools that enhance the efficiency and effectiveness of ophthalmic drug research.

Glaukos
glaukos.com

Spyglass Pharma
spyglasspharma.com

SpyGlass Ophthalmics

Adtech Pharma
adtechpharma.com

Ocular Therapeutix
ocutx.com

Visiox
visioxpharma.com

Glycologix
glycologix.com

EyeCyte
eyecyte.com

Orange Grove Bio
orangegrovebio.com

Greenstone Biosciences

Xontogeny
xontogeny.com

Ocular Science
ocularscience.com

Endogenx

GeneCentrix
genecentrix.com

Surface Pharmaceuticals
surfacepharma.com
Companies similar to Glauconix Biosciences include Glaukos, Spyglass Pharma, SpyGlass Ophthalmics and Adtech Pharma.
Glauconix Biosciences was founded in 2014.
Glauconix Biosciences' headquarters is located in Albany, NY, US.
Glauconix Biosciences' most recent funding round was for $100k (USD) in May 2018.
As of May 31, 2018, Glauconix Biosciences has raised a total of $2.2M (USD).
Glauconix Biosciences has 8 employees as of Feb 4, 2024.